Furosemide Decreases Bladder Radioactivity With ¹⁸F PSMA-1007 PET-CT Imaging

Background: Prostate-specific membrane antigen (PSMA) radiolabeled PET agents have been introduced, which have demonstrated value in detecting prostate cancer. The specific agent, 18 F-PSMA-1007, has been considered promising since its excretion is primarily hepatobiliary, resulting in lower interference from bladder activity. Use of furosemide might further decrease this undesirable bladder activity. Objective: To determine whether the use of furosemide with 18 F-PSMA-1007 PET/CT imaging would decrease the amount of radioactivity in the bladder detected on the images. Design: Single-center, retrospective, intra-individual comparative analysis. Participants: Patients who had undergone 2 consecutive 18 F-PSMA-1007 PET/CT scans between January 2020 and November 2023 at a tertiary care center in Switzerland; 1 scan with and 1 scan without the furosemide protocol. Methods: Each patient received 250 MBq 18 F-PSMA-1007 IV and were scanned 60 minutes later. For the furosemide protocol, 20 m more...